Bangwei Cao

Bangwei Cao

Auto-generated profile, based on publicly available information

Bangwei Cao

Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
ZGZhengxing Gao
Zhengxing Gao
CSChunqing Song
Chunqing Song
GLGuangxin Li
Guangxin Li
HLHaishan Lin
Haishan Lin
XLXiangyao Lian
Xiangyao Lian
BCBangwei Cao
Bangwei Cao
Aims: Pyrotinib is a newly developed irreversible pan-ErbB receptor tyrosine kinase inhibitor for treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers, and clinic trials of pyrotinib in treatment of HER2-positive gastric cancer (GC) are underway. Exosomes are tiny vesicles secreted by cancer cells and take essential roles in the progression of carcinoma. Whether pyrotinib application has any effect on the cancer cell-released exosomes has not been studied. The aim of our work was to address if pyrotinib treatment impacts the effect of HER2-positive GC cell-derived exosomes on endothelial cell (EC) progression. Methods: Isolation of exosomes released by HER2-positive NCI-N87 and MKN45 lines after pyrotinib treatment was performed. Then, human umbilical vein endothelial cells (HUVECs) were incubated with different concentrations of exosomes to address their proliferation by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS). Effect of pyrotinib-treated exosomes at concentration of 10 μg/mL was compared to that without pyrotinib treatment over 96-hr time course. Transwell assay and wound-healing assay were carried out by incubating with exosomes released by NCI-N87 and MKN45 cells with/without pyrotinib treatment over 24-hr time course. The aforementioned experiments were done under same conditions in order to evaluate the combined effect of apatinib and pyrotinib on HUVEC motility and invasive capacity. Results: We showed that HUVEC proliferation, motility and invasive capacity were further enhanced upon incubation with exosomes released by pyrotinib-treated GC cell lines, compared to those without pyrotinib treatment. Significantly, this effect was counteracted by the vascular endothelial growth factor receptor (VEGFR)-2 inhibitor apatinib which inhibits EC progression. Conclusion: Our study suggests that pyrotinib application on HER2-positive GC produces stronger exosomes that promote the proliferation and motility of vascular ECs, and combination of pyrotinib with apatinib provides potentially better therapy.

18 February 2020 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
XLXiangyao Lian
Xiangyao Lian
CZCuimin Zhu
Cuimin Zhu
HLHaishan Lin
Haishan Lin
ZGZhengxing Gao
Zhengxing Gao
GLGuangxin Li
Guangxin Li
YKYan Kang
Yan Kang
Radiation therapy is a widely used treatment for esophageal cancer. However, radiation resistance might result in a poor prognosis. Overexpression of HER2 has been related to adaptive radiation resistance. Pyrotinib is a HER2 inhibitor that shows an anti-tumor effect in breast cancer. The present study aims to explore the influence of pyrotinib combined with radiotherapy on HER2-positive esophageal cancer cells and explore the underlying mechanism. We screened two cell lines (TE-1 and KYSE30) that highly express HER2 from several human esophageal cancer cell lines. Cells were treated with pyrotinib or/and radiation. Cell proliferation, cell cycle distribution, and cell migration were measured. The protein levels involved in cell cycle and DNA repair were measured by Western blot. Results showed that pyrotinib inhibited HER2 activation and exerted an anti-proliferative effect in TE-1 and KYSE30 cells. Furthermore, it enhanced the anti-proliferative effect of radiation in these two cell lines. These effects might be via inhibiting HER2 phosphorylation, inducing G0/G1 arrest, and reducing EMT and DNA repair. Our results indicated that pyrotinib sensitivitied HER2 positive esophageal cancer cells to radiation treatment through various mechanisms. These findings may provide a new therapeutic strategy for treating HER2 positive esophageal cancer.

1 January 2006 in World Chinese Journal of Digestology
Verified
Journal Article
Open access
BCBang-Wei Cao
Bang-Wei Cao
YDYue Dai
Yue Dai
YGYu-Hui Gai
Yu-Hui Gai
QCQing-Bo Chai
Qing-Bo Chai
XWXin Wang
Xin Wang
目的: 探讨中国汉族人群中肿瘤抗原递呈的限速基因LMP2/LMP7单核苷酸多态性与胃癌的遗传易感性关联. 方法: 提取145例胃癌患者及152例健康献血员外周血基因组DNA, 用PCR-RFLP方法检测两组人群中LMP2-codon60/LMP7-codon145两个多态性位点的基因型; 并采用PHASE1.0软件构建这两个多态性位点的个体单倍体型, 以非条件Logistic回归校正混杂因素, 并进行多态性与胃癌患者风险关联的统计学分析. 结果: PCR-RFLP检测结果显示: LMP2-codon60与LMP7-codon145处的多态性在中国人群中普遍存在, LMP2/LMP7多态性位点的各自的等位基因频率分布符合Hardy-Weinberg平衡定律; 最后的统计分析表明: 在145例胃癌患者与152例健康对照人群中LMP2/LMP7两个多态性位点的基因型频率、以及所构建的4个单倍体型频率均没有统计学差异(P值均大于0.05). 结论: 在中国汉族人群中, LMP2/LMP7基因编码区两个位点的多态性以及单倍体型与胃癌易感无相关性.